Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose
Schlieren , Switzerland, and Gaithersburg, MD, USA - October 17, 2023 - ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational.
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors
ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.